ABSTRACT-We have investigated the effect of NZ-107, an inhibitor of bronchocon striction induced by slow reacting substance of anaphylaxis (SRS-A), on tracheal re sponses to adenosine in the guinea pig. In the presence of an adenosine uptake inhibi tor, dipyridamole (1 ,u M), NZ-107 (0.3-1 uM) enhanced adenosine-induced relaxa tion in 30 nM leukotriene D4 (LTD4)-precontracted trachea, whereas aminophylline (AP, 10-30 uM), an adenosine receptor antagonist, markedly inhibited it. NZ-107 (1 p M) also enhanced the relaxation induced by forskolin, an adenylate cyclase activa tor, but not that by nitroprusside (NP), a guanylate cyclase activator. AP (30 PM) affected neither forskolin nor NP-induced relaxation. NZ-107 (1 UM) and AP (30 pM) inhibited to about the same extent the contractile response to an adenosine A, receptor agonist, the R(-)-enantiomer of N6-(2-phenylisopropyl)-adenosine (R-PIA). The R-PIA-induced contraction was completely blocked by 5 pM indomethacin. NZ 107 (1 pM) did not affect the contraction induced by PGD2, but significantly reduced that of PGF2a . AP (30 p M) had no effect on PGF20 and PGD2-induced contractions. These results suggest that NZ-107 may have a unique profile for adenosine responses in bronchial asthma.
NZ-107 is an orally active and potent inhibi tor of bronchoconstriction induced by slow reacting substance of anaphylaxis (SRS-A) in the guinea pig (1) . In isolated trachea and lung parenchyma, NZ-107 more selectively in hibited antigen-induced contraction than that induced by the calcium ionophore A23187, and it also selectively inhibited antigen-in duced SRS-A release from lung fragments (2) . These profiles of NZ-107 suggested that it may be beneficial in the treatment of SRS-A pre dominant bronchial asthma.
Allergic mediators, leukotrienes (LT) (3), histamine and platelet activating factor (4), are thoroughly implicated in the pathogenesis of asthma. There is also increasing interest in the involvement of adenosine as a mediator in allergic asthma (5, 6) . Adenosine is reported to be a potent bronchoconstrictor in allergic and non-allergic asthmatic subjects (6) and in allergic rabbits (7) , and allergen-induced bron chospasm in asthmatics is associated with ele vated plasma concentrations of adenosine (8) .
Methylxanthine derivatives, such as theo phylline and its diethylene salt aminophylline (AP), are widely used in the treatment of bronchial asthma. Theophylline at its thera peutic plasma concentration is only a weak in hibitor of phosphodiesterase (PDE) enzymes (9) , but is an effective antagonist of adenosine receptors (5) . The other mechanism of action of theophylline has been reported to be an tagonism against prostaglandins (PGs) (10) .
We, therefore, investigated the effect of NZ-107 on adenosine receptor-mediated re laxation and contraction in the isolated guinea pig trachea, and the results were compared with those for AP.
MATERIALS AND METHODS

Materials
The following materials were used for these studies: adenosine, nitroprusside sodium (NP), histamine dihydrochloride (Wako Pure Chemi cals, Japan); R(-)-enantiomer of N`'-2 phenylisopropyl-adenosine (R-PIA) (Research Biochemicals, MA); aminophylline, dipyrida mole, indomethacin (Sigma Chemical Co., MO); leukotriene D4 (LTD4, Ultrafine Chemi cals, U.K.); forskolin (Calbiochem, CA); prostaglandin F2a (PGF2a , Nacalai Tesque, Japan); and prostaglandin D2 (PGD2, Funa koshi, Japan). NZ-107 was synthesized by the Central Research Laboratory, Nissan Chemi cal Industries, Ltd. (Funabashi, Japan).
Methods
Generals: Male albino Hartley guinea pigs (300-500g) were killed by a blow to the head. The trachea was removed and spirally cut and divided into two or three segments. Each was suspended under 1 g tension in an 8 ml organ bath containing modified Tyrode solution maintained at 37°C and aerated with 95% 02 and 5% CO-,. The composition of the modified Tyrode solution was as follows: 137 mM NaCl, 2.7 mM KCI, 1.8 mM CaCl2, 1.0 MM MgCl2, 0.3 mM NaHPO4, 20 mM NaHCO3 and 11 mM dextrose. Responses were recorded isotonically (Nihon Kohden, Type TD-112S).
Effect of NZ-107 on the relaxants: Tissues were equilibrated for 50-60 min, and then the maximal response to histamine (100 ,u M) was obtained in each tissue. After the response reached a plateau, tissues were washed several times for 20 min until resting level tone was restored. Indomethacin (5 ,aM), dipyridamole (1 uM, in the experiment of adenosine), and NZ-107 or AP were added to the organ bath 30 min before LTD4 was added. After the contractile response of LTD4 reached a plateau, the relaxant was added cumulatively. The maximum response was obtained by 1 mM AP.
Effect of NZ-107 on constrictors: NZ-107 (0.3 or 1 uM) or AP (10 or 30 ,uM) and in domethacin (when PGs were used as constric tors) were administered to the organ bath 30 min before R-PIA or PGs were cumulatively added. The contractile responses were ex pressed as a percentage of the maximum re sponse to histamine (100 ,uM). Other ex perimental conditions were similar to those of the relaxation experiment.
Statistics: Results are expressed as the mean ± S.E.M. pEC5u was calculated from the negative logarithm of the concentration (mo lar) of compound required to induce 50% of the response. Statistical analysis was per formed by Student's t-test or the paired t-test. P values of less than 0.05 were considered to be significant.
RESULTS
Effect of NZ-107 on adenosine-induced relaxa tion
In the presence of indomethacin and dipyr idamole, adenosine (over 1 u M) caused concentration-dependent relaxation against 30 nM LTD4-induced contraction, and the max imal response was obtained at 300,uM adeno sine (90% relaxation as compared with 1 mM AP) (Fig. 1) . NZ-107 (0.3 and 1 u M) caused a leftward shift of the concentration-relaxation curve to adenosine. In contrast, AP (10 and 30,uM) caused a rightward shift of the curve. NZ-107 (1 ,uM) partly inhibited 30 nM LTD4 induced contraction, producing a level of con traction similar to the control response to 3 nM LTD4. We, therefore, compared the pEC50 value between similar levels of contrac tile response (11) . The pEC5O value in the pres ence of NZ-107 (1 uM) was significantly in creased as compared with 3 nM LTD4 ( Table  1) . In contrast, the pEC50 values in the pres ence of AP (10 and 30 ,u M) were markedly re duced as compared with the control.
Effect of NZ-107 on forskolin and NP-induced relaxation
Both an adenylate cyclase activator, forsko lin (12) , and a guanylate cyclase activator, NP (13), caused concentration-dependent relaxa tion against the contraction induced by 30 nM LTD4 in the presence of indomethacin. The pEC50 value for each relaxant is shown in Table 2 . Preincubation of NZ-107 (1 uM) or AP (30 MM) attenuated 30 nM LTD4-induced contraction to the same extent (less that about 15% inhibition, Table 2 ). NZ-107 appeared to enhance the relaxant response induced by forskolin but not that by NP. AP did not en hance the response of either relaxant. (14), which is relatively selective for adenosine A, receptors, contracted guinea pig trachea at concentrations ranging from 0.01-1 ,u M. The maximum response at 1 uM was about 25% of the response to 100,uM histamine (Fig. 2) . Both NZ-107 and AP reduced R-PIA-induced contraction in a concentration-dependent man ner, and 1 u M NZ-107 and 30 ,u M AP signifi cantly reduced it. A cyclooxygenase inhibitor, indomethacin (5 ,u M), completely blocked R PIA-induced contraction (data not shown).
Effect of NZ-107 on contraction induced by PGD2 and PGF20
In a separate experiment, PGF2a produced concentration-dependent contraction in the presence of 5 ,uM indomethacin (Fig. 3, a and  b) . NZ-107 (1 u M) caused a significantly rightward shift of the PGF2a curve (Table 3) , while AP (30 ,u M) did not affect the PGF2a re sponse. PGD2, another constrictor PG, also contracted guinea pig trachea to the same ex tent as PGF2a (Fig. 3, c and d) . Neither NZ 107 (1,uM) nor AP (30,uM) inhibited PGD2 induced contraction (Fig. 3, c and d ; Table 3 ). Table 2 . Effects of NZ-107 and aminophylline (AP) on forskolin and nitroprusside-induced relaxation in the isolated guinea pig trachea 
DISCUSSION
Previous studies showed that two surface re ceptors for adenosine are recognized by substi tute analogues of adenosine. Al receptors are inhibitory to adenylate cyclase and associated with a fall in intracellular cyclic AMP (cAMP), while A2 receptors are stimulatory to adenylate cyclase and associated with a rise in cAMP (15) . At receptors have a high affinity for adenosine (Ka: 5 nM to 50 nM), while A2 receptors show low affinity (Ka: 5 ,u M to 20 ,uM) (15) . In guinea pig trachea, adenosine-in duced relaxation is reported to be mediated by A2 receptors (16, 17) . The stable adenosine analogue R-PIA, which is relatively selective for adenosine Al receptors (14) , elicits a con tractile response in guinea pig trachea at con centrations lower than about 1 uM (18, 19) . In the present study, adenosine caused only relaxation at concentrations higher than 3 uM, and R-PIA caused contraction at concentra tions less than 1 u M, suggesting that adeno sine and R-PIA act on A2 and Al receptors, respectively, in the guinea pig trachea.
It is interesting that NZ-107 enhanced the relaxation of adenosine and inhibited contrac tion of R-PIA, while AP inhibited both the relaxant response and contractile response. These dual inhibitory effects of AP may be due to non-selective antagonism at adenosine Al and A2 receptors. NZ-107, also potentiated the relaxation induced by forskolin but not that by NP. This result suggests that the effect of NZ-107 on adenosine A2 receptor-mediated relaxation is partly mediated by the elevation of cAMP levels. The ineffectiveness of AP on forskolin-induced relaxation may be related to the lack of the increase in cAMP at 30 uM. Farmer (18) reported that a xanthine deriva tive, enprofylline, which is not an adenosine antagonist but a potent PDE inhibitor (20) , had little effect on R-PIA-induced contraction in the guinea pig trachea. Thus it is unlikely that the inhibitory effect of NZ-107 on Al mediated contraction results from PDE inhibi tion. Since the cyclooxygenase inhibitor in domethacin completely inhibited R-PIA-in duced contraction, it is suggested that the con tractile response elicited by R-PIA is mediated by cyclooxygenase metabolites, such as con strictor PGs. Similar results have been re ported by Farmer et al. (18) and Caparrotta et al. (19) . Since NZ-107 (1 ,uM) significantly in hibited the contraction induced by PGF2a, it is suggested that NZ-107 reduces R-PIA-induced contraction by inhibiting the contraction in duced by endogenously released PGF2a. NZ 107, however, did not affect the contractile re sponse of PGD2, another constrictor PG. The reason for the inability of NZ-107 to inhibit the PGD2 response is not clear, but it may be related to the different contractile mechanism between PGD2 and PGF2a, because we have previously found that PGF2a -induced contrac tion is partly conducted by LT-like substances in the guinea pig trachea (21) and NZ-107 is an inhibitor of LTD4 contraction of the guinea pig trachea (1) . Therefore, it is a possible in terpretation that NZ-107 predominantly blocks LTD4 contraction through the involvement of PGF2a rather than PGDZ. We, therefore, sug gest that NZ-107 enhances adenosine A2 mediated relaxation and inhibits adenosine A1-mediated contraction of the guinea pig trachea by elevating the cAMP level and blocking the LTD4 response, respectively. Since AP did not affect PGF2a and PGD2-in duced contraction, the inhibitory effect of AP on R-PIA response is not due to the inhibition of PG but due to adenosine antagonism.
Adenosine is a potent bronchoconstrictor in asthmatic subjects but not in normal subjects (6) . It is possible that adenosine acts preferen tially on the Al receptor and induces broncho constriction in asthmatics. In light of this hypothesis, the inhibitory effect of NZ-107 on R-PIA-induced contraction may be a useful profile for an anti-asthma drug.
In conclusion, NZ-107 enhanced adenosine A2 receptor-mediated relaxation and reduced adenosine Al receptor-mediated contractions at the same concentration in the guinea pig trachea.
